CN108486120B - Novel CpG ODN sequence and application thereof in anti-melanoma - Google Patents

Novel CpG ODN sequence and application thereof in anti-melanoma Download PDF

Info

Publication number
CN108486120B
CN108486120B CN201810402526.0A CN201810402526A CN108486120B CN 108486120 B CN108486120 B CN 108486120B CN 201810402526 A CN201810402526 A CN 201810402526A CN 108486120 B CN108486120 B CN 108486120B
Authority
CN
China
Prior art keywords
cpg odn
melanoma
odn sequence
sequence
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810402526.0A
Other languages
Chinese (zh)
Other versions
CN108486120A (en
Inventor
冯志伟
贾慧婕
李连涛
赵铁锁
郭胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xuzhou Medical University
Xinxiang Medical University
Original Assignee
Xuzhou Medical University
Xinxiang Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xuzhou Medical University, Xinxiang Medical University filed Critical Xuzhou Medical University
Priority to CN201810402526.0A priority Critical patent/CN108486120B/en
Publication of CN108486120A publication Critical patent/CN108486120A/en
Application granted granted Critical
Publication of CN108486120B publication Critical patent/CN108486120B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a novel CpG ODN sequence and application thereof in resisting melanoma. The novel CpG ODN sequence of the invention has strong immune stimulation function, can effectively stimulate the expression of CD86 on PBMC cells, effectively inhibit the growth of melanoma, increase the expression of CD8 positive T lymphocytes in the spleen of a mouse, and has obvious clinical application prospect.

Description

Novel CpG ODN sequence and application thereof in anti-melanoma
Technical Field
the invention belongs to the technical field of biological medicines, and particularly relates to a novel CpG ODN sequence and application thereof in resisting melanoma.
Background
DNA has been considered to have only weak immunogenicity, and is difficult to induce immune response in the body. However, in recent years, it has been found that synthetic deoxyoligonucleotide single-stranded DNA (CpG ODN) containing CpG motif can activate NK cells of mice and stimulate spleen cells of mice to secrete interferon. CpG is an unmethylated dinucleotide composed of cytosine and guanine linked via a phosphodiester bond (where C represents cytosine, G represents guanine, and p represents a phosphodiester bond). Structural conditions that CpG ODN with immune response stimulating ability must have: (1) the stimulatory sequence must contain an unmethylated CpG motif, (2) sequences with two purine nucleotides at the 5 'end and two pyrimidine nucleotides at the 3' end of the CpG motif have a stronger stimulatory effect, and (3) CpG ODN needs to have a certain length. In a CpG ODN, there may be more than one CpG motif. Due to differences in sequence, particularly sequences flanking CpG, CpG ODN can take a wide variety of forms, exhibit different immunomodulatory activities, and the ability of sequences to be immunostimulatory is affected by purine and pyrimidine nucleotides surrounding CpG motifs, as well as the spacing between CpG motifs, and the like. Therefore, the CpG ODN sequence with stronger immunogenicity is designed.
Disclosure of Invention
the novel CpG ODN sequence of the invention has strong immune stimulation function, can effectively stimulate the expression of CD86 on PBMC cells, effectively inhibit the growth of melanoma, increase the expression of CD8 positive T lymphocytes in the spleen of a mouse, and has obvious clinical application prospect.
The invention provides a novel CpG ODN sequence, and the nucleotide sequence of the novel CpG ODN sequence is as follows:
5’-gacgcgcgtcgacgatcgcgaattcgaacgtacgct-3’。
An application of the novel CpG ODN sequence in resisting melanoma.
Preferably, the novel CpG ODN sequences are applied to the expression of the PBMC cell surface molecule CD86 in melanoma patients.
preferably, the novel CpG ODN sequence is prepared as a drug for treating melanoma mice.
Compared with the prior art, the invention has the beneficial effects that:
the novel CpG ODN sequence of the invention has strong immune stimulation function, can effectively stimulate the expression of CD86 on PBMC cells, causes the immune response of organisms and effectively inhibits the growth of melanoma; increase the expression of CD4 and CD8 positive T lymphocytes in the spleen of the mouse, inhibit the growth of melanoma of the mouse, prolong the life cycle of the mouse and have obvious clinical application prospect.
Drawings
FIG. 1 is a diagram showing the expression of the PBMC cell surface molecule CD 86;
FIG. 2 is a graph of survival of melanoma-bearing mice of the present invention;
FIG. 3 is a tumor entity map of a melanoma-bearing mouse of the present invention (A);
FIG. 4 is a graph of tumor weight for melanoma-bearing mice of the present invention (B);
FIG. 5 is a graph showing the expression of CD4 and CD8 positive T lymphocytes according to the invention;
FIG. 6 is a graph showing the expression of migration and apoptosis-related proteins in tumor tissues according to the present invention;
FIG. 7 is a graph showing the content of anti-tumor cytokine IFN γ in the serum of mice of the present invention.
Detailed Description
several embodiments of the present invention will be described in detail below with reference to fig. 1-7, but it should be understood that the scope of the present invention is not limited to the embodiments, and the reagents involved in the examples can be obtained through common channels.
example 1
a novel CpG ODN sequence, the nucleic acid sequence of the novel CpG ODN sequence is:
5'-gacgcgcgtcgacgatcgcgaattcgaacgtacgct-3', as shown in SEQ ID NO. 1.
The novel CpG ODN sequence has the effect of resisting melanoma and can be applied to the expression of a PBMC cell surface molecule CD86 of a melanoma patient.
in order to verify the application effect of the invention, the following tests were carried out:
(1) Preparing a PBMC cell solution of a melanoma patient, and adjusting the cell concentration to be more than or equal to 1 multiplied by 106 per ml;
(2) inoculating PBMC cells into AIM-V culture medium in a 6-well plate, and incubating at 37 deg.C and 5% CO2 by volume in an incubator;
(3) after the monocytes are adhered to the surface, rhGM-CSF and IL-4 are added, and the test group is incubated for 3 days after CpG ODN (control group is added with equal amount of physiological saline) is added according to the mass concentration of 1 mu g/ml, and the expression of CD86 cell surface molecules is detected by FACS. The results are shown in fig. 1, the left panel is the control group, the expression number of CD86 molecules on the surface of PBMC cells is 5.65%, and the expression number of the right panel is 9.39%, so the CpG ODN sequence of the present application can effectively enhance the expression of the human PBMC surface costimulatory molecule CD 86.
Example 2
A novel CpG ODN sequence, the nucleic acid sequence of the novel CpG ODN sequence is:
5'-gacgcgcgtcgacgatcgcgaattcgaacgtacgct-3', as shown in SEQ ID NO. 1.
the novel CpG ODN sequence is prepared into a medicament for treating melanoma mice.
in order to verify the application effect of the invention, the following tests were carried out:
1. establishing a mouse melanoma model:
(1) Digesting and resuspending melanoma cells B16, counting, calculating the ratio of viable cells, and selecting a sample with the ratio of the viable cells being more than or equal to 98% for later use;
(2) Preparing a melanoma cell sample with the ratio of live cells being more than or equal to 98% into a cell suspension by using a serum-free culture medium, adjusting the concentration to be more than or equal to 1 multiplied by 107 cells/ml, refrigerating, and injecting 0.1ml subcutaneously at a position which is close to the root of the tail and is about 0.7cm below the lower part of the right side of the mouse;
(3) After injection of melanoma cells, mice with skin cumulus of 6-8mm in diameter in the injection area were selected as animal test mice.
2. Mouse animal test:
(1) the animal test mice 7 days after the inoculation were randomly divided into three groups: PBS group, CpG ODN 1 group and CpG ODN 2 group, wherein the PBS group is controlled by normal saline 20 mug/piece each time, the CpG ODN 1 group dosage is 10 mug/piece each time, the CpG ODN 2 group dosage is 20 mug/piece each time, the injection mode is as follows: the inguinal lymph node drainage area of the test mouse is injected once every other day for four times;
(2) the differences in survival time of the mice were observed, and the results are shown in FIG. 2;
(3) after 14 days of the last treatment, the melanoma tissues of the test mice are separated, and the growth conditions of the melanoma tissues of each group are observed, and the results are shown in figures 3-4; FACS is used for detecting CD4+ and CD8+ T in the spleen of the tumor-bearing mouse, and the result is shown in FIG. 5; the results of detecting the expression of proteins related to melanoma migration and apoptosis in tissues are shown in FIG. 6; the results of measuring IFN γ levels in serum using Elisa are shown in FIG. 7.
As can be seen from fig. 2, the survival rate of the melanoma-bearing mice injected with the novel CpG ODN sequence group is higher than that of the mice injected with the physiological saline, and the effect of the CpG ODN 2 group is better than that of the CpG ODN 1 group, so that the novel CpG ODN sequence can effectively prolong the survival time of the melanoma-bearing mice.
from fig. 3 to fig. 4, it can be seen that the size and weight of the tumor of the melanoma-bearing mice injected with the novel CpG ODN sequence group are both significantly smaller than those of the normal saline group, so that the novel CpG ODN sequence can effectively inhibit the tumor growth of the melanoma-bearing mice.
FIG. 5 shows the ratio of CD4 and CD8 positive T lymphocytes in splenocytes detected by flow cytometry after incubation with antibodies labeled with different color fluorescence CD4 and CD 8. The CD4T cell ratio was 23.5. + -. 2.6 for the CpG ODN 20. mu.g group and 20.3. + -. 2.1 for the CD8T cell ratio, both of which were greater than the CD4T cell ratio and the CD8T cell ratio for the PBS group and CpG ODN 10. mu.g, respectively. It can be seen that the novel CpG ODN sequence significantly increased the ratio of CD4T cells and CD8T cells in splenocytes from melanoma-bearing mice. Therefore, the novel CpG ODN sequence improves the anti-tumor immune response of mice
FIG. 6 shows that the expression level of apoptosis-related protein Cleaved-Caspase3 in the CpG ODN 2 group is the most, and the expression of migration-related protein MMP2 is obviously inhibited, which indicates that the novel CpG ODN sequence can effectively inhibit the tumor growth of melanoma mice.
Fig. 7 shows that the content of IFN γ, which is an antitumor cytokine, in serum was the highest in the CpG ODN 2 group, and that the novel CpG ODN sequence had an antitumor effect.
In conclusion, the novel CpG ODN sequence can effectively improve the expression of PBMC (peripheral blood mononuclear cell) co-stimulatory molecules, inhibit the growth of melanoma of mice, improve the anti-tumor immune response of the mice and have certain application value.
it should be noted that the steps and methods adopted in the claims of the present invention are the same as those of the above-mentioned embodiments, and for the sake of avoiding redundancy, the present invention describes the preferred embodiments, but those skilled in the art can make other changes and modifications to these embodiments once they learn the basic inventive concept. Therefore, it is intended that the appended claims be interpreted as including preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
it will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Sequence listing
<120> novel CpG ODN sequence and application thereof in anti-melanoma
<141> 2018-04-23
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 36
<212> DNA
<213> Artificial sequence
<400> 1
gacgcgcgtc gacgatcgcg aattcgaacg tacgct 36

Claims (4)

1. A novel CpG ODN sequence, wherein the nucleic acid sequence of the novel CpG ODN sequence is:
5’-gacgcgcgtcgacgatcgcgaattcgaacgtacgct-3’。
2. Use of a novel CpG ODN sequence according to claim 1 for the preparation of an anti-melanoma drug.
3. The use of the novel CpG ODN sequence of claim 2 in the preparation of an anti-melanoma drug, wherein the novel CpG ODN sequence is used for expression of the PBMC cell surface molecule CD86 in melanoma patients.
4. The use of the novel CpG ODN sequence of claim 2 for the preparation of an anti-melanoma drug, wherein the novel CpG ODN sequence is prepared as a drug for the treatment of melanoma mice.
CN201810402526.0A 2018-04-28 2018-04-28 Novel CpG ODN sequence and application thereof in anti-melanoma Active CN108486120B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810402526.0A CN108486120B (en) 2018-04-28 2018-04-28 Novel CpG ODN sequence and application thereof in anti-melanoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810402526.0A CN108486120B (en) 2018-04-28 2018-04-28 Novel CpG ODN sequence and application thereof in anti-melanoma

Publications (2)

Publication Number Publication Date
CN108486120A CN108486120A (en) 2018-09-04
CN108486120B true CN108486120B (en) 2019-12-06

Family

ID=63313483

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810402526.0A Active CN108486120B (en) 2018-04-28 2018-04-28 Novel CpG ODN sequence and application thereof in anti-melanoma

Country Status (1)

Country Link
CN (1) CN108486120B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109966482A (en) * 2019-01-28 2019-07-05 新乡医学院 A kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application
CN117925665B (en) * 2024-01-25 2024-08-16 新乡医学院第三附属医院 IDO2 recombinant protein vaccine and construction method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059041A2 (en) * 2005-11-11 2007-05-24 Pfizer, Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
CN101268101A (en) * 2005-07-07 2008-09-17 科利制药集团公司 Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2015028574A1 (en) * 2013-08-28 2015-03-05 Pci Biotech As Compound and method for vaccination and immunisation
WO2015143328A1 (en) * 2014-03-20 2015-09-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
CN107428813A (en) * 2014-12-31 2017-12-01 查克美特制药公司 Combine tumour immunotherapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101268101A (en) * 2005-07-07 2008-09-17 科利制药集团公司 Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2007059041A2 (en) * 2005-11-11 2007-05-24 Pfizer, Inc. Combinations and methods of using an immunomodulatory oligodeoxynucleotide
WO2015028574A1 (en) * 2013-08-28 2015-03-05 Pci Biotech As Compound and method for vaccination and immunisation
WO2015143328A1 (en) * 2014-03-20 2015-09-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
CN107428813A (en) * 2014-12-31 2017-12-01 查克美特制药公司 Combine tumour immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bernd Jahrsdörfer, M.D.等.CpG oligodeoxynucleotides as immunotherapy in cancer.《Update Cancer Ther.》.2008,第3卷(第1期),27–32. *

Also Published As

Publication number Publication date
CN108486120A (en) 2018-09-04

Similar Documents

Publication Publication Date Title
US11896616B2 (en) Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CN101918544B (en) Method for increasing immunoreactivity
CN101400785B (en) Method for production of t cell population
CN106834228A (en) A kind of method of amplification in vitro CD8+T cells and its cell subsets
CN107929727A (en) A kind of preparation method of new dendritic cell vaccine
CN107384930A (en) Non-coding immunological regulation DNA constructs
CN118750590A (en) Methods and compositions for treating cancer using antisense molecules
CN111690050B (en) TCR recognizing EBV-LMP2 antigen and corresponding nucleic acid molecule, vector, cell and drug
CN103484429A (en) Method for preparing NK (natural killer) cell
Landi et al. Dendritic cells matured by a prostaglandin E2-containing cocktail can produce high levels of IL-12p70 and are more mature and Th1-biased than dendritic cells treated with TNF-α or LPS
CN108486120B (en) Novel CpG ODN sequence and application thereof in anti-melanoma
CN102027104A (en) Method for production of cell mass containing cytokine-induced killer cell
CN102994515A (en) Allogeneic tumor therapeutic agent
CN107921063A (en) For the composition and method using dengue virus and the conjoint therapy of dendritic cells
WO2023123195A1 (en) Engineered immune cell target gene of which can be regulated, preparation method therefor, and use thereof
CN108753920A (en) A method of detection RANKL target therapeutic agent biological activities
CN103936862A (en) Co-expression of fusion porcine interleukin 4/6 and interleukin 2 genes and application of fusion porcine interleukin 4/6,2 gene in preparation of biological agents
Lora et al. FcεRI-dependent gene expression in human mast cells is differentially controlled by T helper type 2 cytokines
CN101701218B (en) Immune regulatory oligodeoxynucleotide for inhibiting differentiation of Th1 and Th17 and application thereof
CN102002493B (en) Application of small RNA-326 in preparation of medicament
CN101321861B (en) Method for generating dendritic cells employing decreased temperature
CN109486761A (en) The cultural method of peripheral blood CTL cell
CN107574149A (en) A kind of efficient rush maturation method of BMDC and application thereof
US20050203037A1 (en) Complex immuno-gene medical composition for inhibiting tumor cells
Wang et al. CpG-independent synergistic induction of β-chemokines and a dendritic cell phenotype by orthophosphorothioate oligodeoxynucleotides and granulocyte-macrophage colony-stimulating factor in elutriated human primary monocytes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant